Antiviral Drugs - United Arab Emirates

The Antiviral Drugs market in the United Arab Emirates is forecasted to achieve a revenue of US$79.07m in 2024.
It is anticipated that the revenue will experience an annual growth rate (CAGR 2024-2029) of 2.95%, leading to a market volume of US$91.43m by 2029.
When compared globally, United States is expected to generate the highest revenue in the market, reaching US$30.64bn in 2024.
The United Arab Emirates is witnessing an increasing demand for antiviral drugs due to the high prevalence of viral diseases in the region.

Definition:
The Antiviral Drugs market includes treatments against viruses and virus-induced conditions, such as human immunodeficiency viruses (HIV), hepatitis B and C viruses (HBV and HCV), and Ebola. Therapies for the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are also included. HIV therapies also encompass highly active antiretroviral therapies (HAART) and post-exposure prophylaxis. In contrast to antibiotics, antivirals do not destroy the virus but rather inhibit its development.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, AbbVie, Merck

HIV
Hepatitis B and hepatitis C
Ebola
COVID-19

Vaccines
Antibiotics
Immunosuppressants
In vitro diagnostics and rapid tests

The Antiviral Drugs market in United Arab Emirates has witnessed significant growth in recent years, driven by various factors such as increasing awareness about viral infections, rising healthcare expenditure, and the growing prevalence of viral diseases.

Customer preferences: Customers in the United Arab Emirates are increasingly opting for antiviral drugs as a preventive measure against viral infections. This is mainly due to the rising incidence of viral diseases such as influenza, hepatitis, and HIV/AIDS in the region. Additionally, the growing awareness about the benefits of antiviral drugs in treating viral infections has also contributed to the increased demand for these drugs.

Trends in the market: One of the major trends in the Antiviral Drugs market in United Arab Emirates is the increasing use of combination therapies. Combination therapies involve the use of two or more antiviral drugs to treat viral infections. This approach has been found to be more effective in treating viral infections than using a single drug. Another trend in the market is the growing popularity of generic antiviral drugs. Generic drugs are cheaper than branded drugs and are becoming increasingly popular among patients who cannot afford expensive branded drugs.

Local special circumstances: The United Arab Emirates has a high prevalence of viral diseases such as hepatitis and HIV/AIDS. This has led to a high demand for antiviral drugs in the country. Additionally, the government of the United Arab Emirates has taken various initiatives to improve the healthcare infrastructure in the country, which has also contributed to the growth of the Antiviral Drugs market.

Underlying macroeconomic factors: The Antiviral Drugs market in United Arab Emirates is also being driven by various macroeconomic factors such as increasing healthcare expenditure and the growing population. The government of the United Arab Emirates has been investing heavily in the healthcare sector, which has led to the development of world-class healthcare infrastructure in the country. Additionally, the growing population in the country has also contributed to the increased demand for healthcare services, including antiviral drugs.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.